<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- April 11 2024 ASKA Pharmaceutical Achieves the Primary Endpoint of Phase III Clinical Trial on LF111 in Japan
- April 1 2024 ASKA Pharmaceutical Initiates “Work Support Grant” Program and Cancer Insurance Program for All Regular Employees
- April 1 2024 Organizational and Personnel Changes of ASKA Pharmaceutical
- March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication
- March 21 2024 Newsweek International Features ASKA Pharmaceutical
- March 18 2024 Red Arrow Therapeutics and ASKA Pharmaceutical Sign Joint Research Agreement on Novel Preeclampsia Treatment
- February 22 2024 Organizational and Personnel Changes of ASKA Pharmaceutical
- January 18 2024 ASKA Pharmaceutical Invests in NEXTBLUE Fund 2, a Fund Specializing in the Realm of Women's Wellbeing
- January 15 2024 ASKA Pharmaceutical Executes Capital Increase to Ha Tay Pharmaceutical Joint Stock Company
- November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine
- September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo
- September 21 2023 ASKA Pharmaceutical Launches Training Videos on Women's Health
- September 14 2023 Newsweek International Features ASKA Pharmaceutical
- August 25 2023 Organizational and Personnel Changes of ASKA Pharmaceutical
- July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)
- June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries
- June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA
- June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma
- April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech
- April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities
- April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment
- April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone
- April 3 2023 ASKA Pharmaceutical and Future Venture Capital Co-found a Corporate Venture Capital Fund
- March 27 2023 Personnel Change of ASKA Pharmaceutical
- March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical
- February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology
- December 28 2022 ASKA Pharmaceutical Obtains the Additional Approval of an Indication of FREWELL® COMBINATION TABLETS LD/ULD “ASKA” for the Infertility Treatment
- September 30 2022 ASKA Pharmaceutical Holdings Participates at 1st Femtech Tokyo
- September 30 2022 ASKA Pharmaceutical Terminates Joint Research and Development Agreement with RIBOMIC
- September 26 2022 Personnel Changes of ASKA Pharmaceutical
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.